Vor Biopharma Inc. (VOR)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
16.59 USD
+1.62
(10.822%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 16.58 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:52 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 1:16 p.m. EDT
Options speculators are positioning for a short-term decline, with heavy put buying at deep OTM strikes and elevated ATM put IV, despite recent price spikes and analyst optimism. The forecasting model's -7.5% price drop prediction reinforces this bearish bias. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.091630 |
| AutoARIMA | 0.092160 |
| AutoTheta | 0.092262 |
| AutoETS | 0.092299 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.315 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 810,380,096 |
| Forward P/E | -4.48 |
| Beta | 1.92 |
| Website | https://www.vorbio.com |
As of April 18, 2026, 1:16 p.m. EDT: Puts show higher open interest (2.2k) and volume (53) compared to calls (19.1k OI, 640 vol), with significant OI at deep OTM strikes ($1.50-$2.00). ATM put IV is 50% vs. 0% for calls, signaling bearish sentiment. Calls are concentrated in deep ITM strikes ($5.00), suggesting hedging or long-dated bullish bets, but low IV implies limited conviction. Overall, options flow leans mildly bearish.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2091837 |
| Address1 | 100 Cambridgepark Drive |
| Address2 | Suite 101 |
| All Time High | 1,272.4 |
| All Time Low | 2.62 |
| Ask | 16.63 |
| Ask Size | 4 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,359,290 |
| Average Daily Volume3 Month | 1,006,714 |
| Average Volume | 1,006,714 |
| Average Volume10Days | 1,359,290 |
| Beta | 1.923 |
| Bid | 16.52 |
| Bid Size | 7 |
| Board Risk | 10 |
| Book Value | -8.096 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.59 |
| Current Ratio | 18.2 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 16.86 |
| Day Low | 15.0 |
| Display Name | Vor Biopharma |
| Earnings Timestamp | 1,774,873,800 |
| Earnings Timestamp End | 1,778,848,200 |
| Earnings Timestamp Start | 1,778,848,200 |
| Ebitda | -339,048,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.056 |
| Enterprise Value | 358,172,096 |
| Eps Current Year | -3.3877 |
| Eps Forward | -3.70438 |
| Eps Trailing Twelve Months | -70.5 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.6121 |
| Fifty Day Average Change | 1.9779005 |
| Fifty Day Average Change Percent | 0.13536046 |
| Fifty Two Week Change Percent | 20.91837 |
| Fifty Two Week High | 65.8 |
| Fifty Two Week High Change | -49.210003 |
| Fifty Two Week High Change Percent | -0.74787235 |
| Fifty Two Week Low | 2.62 |
| Fifty Two Week Low Change | 13.97 |
| Fifty Two Week Low Change Percent | 5.3320613 |
| Fifty Two Week Range | 2.62 - 65.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 36,521,813 |
| Forward Eps | -3.70438 |
| Forward P E | -4.4784822 |
| Free Cashflow | -180,674,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04754 |
| Held Percent Institutions | 0.59743 |
| Implied Shares Outstanding | 48,847,504 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,758,240,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Vor Biopharma Inc. |
| Market | us_market |
| Market Cap | 810,380,096 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_572078292 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -695,980,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 809,403,141 |
| Number Of Analyst Opinions | 8 |
| Open | 15.12 |
| Operating Cashflow | -142,712,992 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 617 655 6580 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.060278654 |
| Post Market Price | 16.58 |
| Post Market Time | 1,776,469,972 |
| Previous Close | 14.97 |
| Price Eps Current Year | -4.8971276 |
| Price Hint | 2 |
| Price To Book | -2.0491602 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.085 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 1.62 |
| Regular Market Change Percent | 10.8216 |
| Regular Market Day High | 16.86 |
| Regular Market Day Low | 15.0 |
| Regular Market Day Range | 15.0 - 16.86 |
| Regular Market Open | 15.12 |
| Regular Market Previous Close | 14.97 |
| Regular Market Price | 16.59 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,147,845 |
| Return On Assets | -0.70413 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 48,847,504 |
| Shares Percent Shares Out | 0.1164 |
| Shares Short | 5,687,983 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,386,872 |
| Short Name | Vor Biopharma Inc. |
| Short Percent Of Float | 0.1267 |
| Short Ratio | 5.43 |
| Source Interval | 15 |
| State | MA |
| Symbol | VOR |
| Target High Price | 50.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 37.5 |
| Target Median Price | 40.0 |
| Total Cash | 455,208,000 |
| Total Cash Per Share | 9.319 |
| Total Debt | 3,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -70.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.9559 |
| Two Hundred Day Average Change | -7.3659 |
| Two Hundred Day Average Change Percent | -0.30747747 |
| Type Disp | Equity |
| Volume | 2,147,845 |
| Website | https://www.vorbio.com |
| Zip | 2,140 |